Plus Therapeutics (PSTV) News Today $0.73 +0.05 (+7.14%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$0.72 -0.01 (-1.26%) As of 10/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PSTV Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Plus Therapeutics (NASDAQ:PSTV) Earns Buy Rating from D. Boral CapitalSeptember 27, 2025 | americanbankingnews.comPlus Therapeutics (PSTV) Soars 40% as Firm Seals Partnership with United HealthcareSeptember 26, 2025 | insidermonkey.comD. Boral Capital Maintains Plus Therapeutics (PSTV) Buy RecommendationSeptember 25, 2025 | msn.comThese 3 Penny Stocks are Soaring Today: PLUS, EVAX, DVLTSeptember 25, 2025 | 247wallst.comPlus Therapeutics Pops on UNH PactSeptember 25, 2025 | baystreet.caPlus Therapeutics Shares Surge After UnitedHealthcare Coverage DealSeptember 25, 2025 | msn.comPlus Therapeutics stock soars after UnitedHealthcare agreementSeptember 25, 2025 | za.investing.comPlus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS CancerSeptember 25, 2025 | globenewswire.comPlus on Upside on Cancer Institute PaymentSeptember 22, 2025 | baystreet.caPlus Therapeutics announces $1.9M advance payment from CPRITSeptember 22, 2025 | msn.comPlus Therapeutics receives $1.9M CPRIT payment for cancer programSeptember 22, 2025 | msn.comPlus Therapeutics, Inc. Secures $1.9 Million Payment from CPRIT as Part of $17.6 Million Grant for Leptomeningeal Cancer Treatment DevelopmentSeptember 22, 2025 | quiverquant.comQPlus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRITSeptember 22, 2025 | globenewswire.comPlus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical LaboratorySeptember 18, 2025 | finance.yahoo.comCNSide Diagnostics Receives CMS Accreditation for CSF Assay Platform, Advancing Market Access for CNS Cancer TestingSeptember 18, 2025 | quiverquant.comQPlus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical LaboratorySeptember 18, 2025 | globenewswire.comPlus Therapeutics upgraded to Buy from Hold at D. Boral CapitalSeptember 3, 2025 | msn.comD. Boral Capital Upgrades Plus Therapeutics (PSTV)September 3, 2025 | msn.comPlus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | finance.yahoo.comPlus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comPlus Therapeutics Secures Nasdaq Compliance ExtensionAugust 26, 2025 | msn.comPlus Therapeutics, Inc. Confirms Compliance with Nasdaq Listing Rules Ahead of Grace Period ExpirationAugust 26, 2025 | quiverquant.comQPlus Therapeutics Regains Compliance with Applicable Nasdaq Listing CriteriaAugust 26, 2025 | globenewswire.comPlus Therapeutics (NASDAQ:PSTV) Director Acquires $53,900.00 in StockAugust 26, 2025 | insidertrades.comPlus Therapeutics price target lowered to $3 from $4 at MaximAugust 19, 2025 | msn.comPlus Therapeutics presents results from ReSPECT-LM Phase 1 trialAugust 19, 2025 | msn.comPlus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal MetastasesAugust 18, 2025 | globenewswire.comPlus Therapeutics Reports Strong Q2 2025 ResultsAugust 16, 2025 | msn.comPlus Therapeutics Reports $3M in Stock EquityAugust 16, 2025 | baystreet.caPlus Therapeutics Reports $3M in Stock EquityAugust 16, 2025 | baystreet.caPlus Therapeutics reports stockholders’ equity in excess of $2.5MAugust 16, 2025 | msn.comPlus Therapeutics reports stockholders’ equity in excess of $2.5MAugust 16, 2025 | msn.comPlus Therapeutics Reports Stockholders’ Equity in Excess of $2.5 million in Compliance with Nasdaq Equity RequirementsAugust 16, 2025 | finance.yahoo.comPlus Therapeutics Reports Stockholders’ Equity in Excess of $2.5 million in Compliance with Nasdaq Equity RequirementsAugust 16, 2025 | finance.yahoo.comPlus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity RequirementsAugust 15, 2025 | globenewswire.comPlus Therapeutics Reports Second Quarter Financial Results and Recent Business HighlightsAugust 14, 2025 | globenewswire.comPlus Therapeutics presents data from analysis of CNSide CSF AssayAugust 14, 2025 | msn.comPlus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases ConferenceAugust 14, 2025 | finance.yahoo.comPlus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases ConferenceAugust 14, 2025 | globenewswire.comPlus Therapeutics Granted Continued Nasdaq ListingAugust 13, 2025 | msn.comPlus Therapeutics files to sell 33M shares of common stock for holdersAugust 12, 2025 | msn.comPlus Therapeutics Provides US Launch Update for its CNSide® DiagnosticJuly 31, 2025 | globenewswire.comPlus Therapeutics, Inc. Secures $1.6 Million Advance Payment from CPRIT to Support CNS Cancer Research and DevelopmentJuly 23, 2025 | quiverquant.comQPlus Therapeutics Announces $1.6 Million Advance Payment from CPRITJuly 23, 2025 | globenewswire.comPlus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal MetastasesJuly 15, 2025 | finance.yahoo.comPlus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal MetastasesJuly 15, 2025 | globenewswire.comPlus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases ConferenceJuly 10, 2025 | globenewswire.comPlus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases TreatmentJuly 8, 2025 | quiverquant.comQPlus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal MetastasesJuly 8, 2025 | globenewswire.comPSTV - Plus Therapeutics Inc Trailing Returns - MorningstarJuly 2, 2025 | morningstar.comM Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PSTV Media Mentions By Week PSTV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PSTV News Sentiment▼0.910.53▲Average Medical News Sentiment PSTV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PSTV Articles This Week▼03▲PSTV Articles Average Week Get the Latest News and Ratings for PSTV and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Plus Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Monogram Orthopaedics News Today TriSalus Life Sciences News Today Inogen News Today Nano-X Imaging News Today InfuSystem News Today CapsoVision News Today Electromed News Today Biosig Technologies News Today CVRx News Today KORU Medical Systems News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PSTV) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredThese financial titans stride the earth, invisibleUBS says millionaire ranks have surged 5-fold — but many of these new millionaires aren’t tech moguls or Wall ...Porter & Company | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.